chr9-21971112-G-A
Variant summary
Our verdict is Likely pathogenic. The variant received 7 ACMG points: 7P and 0B. PM1PM2PM5PP5
The NM_000077.5(CDKN2A):c.247C>T(p.His83Tyr) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. H83Q) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000077.5 missense
Scores
Clinical Significance
Conservation
Publications
- melanoma, cutaneous malignant, susceptibility to, 2Inheritance: AD Classification: DEFINITIVE Submitted by: G2P
- melanoma-pancreatic cancer syndromeInheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Genomics England PanelApp, ClinGen, Labcorp Genetics (formerly Invitae), Ambry Genetics
- familial atypical multiple mole melanoma syndromeInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- melanoma and neural system tumor syndromeInheritance: AD Classification: LIMITED Submitted by: Ambry Genetics
Genome browser will be placed here
ACMG classification
Our verdict: Likely_pathogenic. The variant received 7 ACMG points.
Transcripts
RefSeq
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| CDKN2A | ENST00000304494.10 | c.247C>T | p.His83Tyr | missense_variant | Exon 2 of 3 | 1 | NM_000077.5 | ENSP00000307101.5 | ||
| CDKN2A | ENST00000579755.2 | c.290C>T | p.Ala97Val | missense_variant | Exon 2 of 3 | 1 | NM_058195.4 | ENSP00000462950.1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD2 exomes AF: 0.00 AC: 0AN: 230846 AF XY: 0.00
GnomAD4 exome Data not reliable, filtered out with message: AC0 AF: 0.00 AC: 0AN: 1451924Hom.: 0 Cov.: 31 AF XY: 0.00 AC XY: 0AN XY: 722664
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Melanoma-pancreatic cancer syndrome Pathogenic:1
This variant is considered likely pathogenic. This variant is expected to disrupt protein structure [Myriad internal data]. Functional studies indicate this variant impacts protein function [PMID: 35001868, 9324288]. This variant has been reported in multiple individuals with clinical features of gene-specific disease [PMID: 21462282, 16234564]. -
Melanoma and neural system tumor syndrome Uncertain:1
- -
Hereditary cancer-predisposing syndrome Uncertain:1
The p.H83Y variant (also known as c.247C>T), located in coding exon 2 of the CDKN2A gene, results from a C to T substitution at nucleotide position 247. The histidine at codon 83 is replaced by tyrosine, an amino acid with similar properties. This alteration was identified in cohorts with sporadic and multiple melanomas (Begg CB et al. J Natl Cancer Inst, 2005 Oct;97:1507-15; Miller PJ et al. Hum Mutat, 2011 Aug;32:900-11). Protein functional studies have shown this variant to have inhibited CDK4 and CDK6 binding and to have increased proliferation activity compared to wild-type (Yang R et al. Cancer Res, 1995 Jun;55:2503-6; Gombart AF et al. Leukemia, 1997 Oct;11:1673-80; Yarbrough WG et al. J Natl Cancer Inst, 1999 Sep;91:1569-74; Kimura H et al. Elife. 2022 Jan;11). This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Another variant at the same codon, p.H83Q (c.249C>A), has been described in families with features of melanoma-pancreatic cancer syndrome (Ambry internal data). Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
Familial melanoma Uncertain:1
The CDKN2A gene encodes two different proteins, p16INK4a and p14ARF, which are translated from alternative transcripts with different open reading frames. Both transcripts have been analyzed. We report either the variant with the higher classification or default to the CDKN2A (p16INK4a) variant. This report therefore includes the details for the CDKN2A (p16INK4a) variant. This sequence change replaces histidine, which is basic and polar, with tyrosine, which is neutral and polar, at codon 83 of the CDKN2A (p16INK4a) protein (p.His83Tyr). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with sporadic and multiple primary melanomas (PMID: 16234564, 16896043, 21462282). This variant is also known as c.290C>T (p.Ala97Val) in the CDKN2A (p14ARF) transcript. ClinVar contains an entry for this variant (Variation ID: 376307). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Experimental studies have shown that this missense change affects CDKN2A (p16INK4a) function (PMID: 7780957, 8521414, 9324288, 10491434). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at